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Atherosclerosis is an inflammatory disease that leads to an aberrant accumulation
of cholesterol in vessel walls forming atherosclerotic plaques. During this process,
the mechanism regulating complex cellular cholesterol pools defined as the reverse
cholesterol transport (RCT) is altered as well as expression and functionality of
transporters involved in this process, namely ABCA1, ABCG1, and SR-BI. Macrophages,
arterial endothelial and smooth muscle cells (SMCs) have been involved in the
atherosclerotic plaque formation. As macrophages are widely described as the major
cell type forming the foam cells by accumulating intracellular cholesterol, RCT alterations
have been poorly studied at the arterial endothelial cell and SMC levels. Amongst
the therapeutics tested to actively counteract cellular cholesterol accumulation, the
methylated β-cyclodextrin, KLEPTOSE® CRYSMEβ, has recently shown promising
effects on decreasing the atherosclerotic plaque size in atherosclerotic mouse models.
Therefore we investigated in vitro the RCT process occurring in SMCs and in arterial
endothelial cells (ABAE) as well as the ability of some modified β-CDs with different
methylation degree to modify RCT in these cells. To this aim, cells were incubated in
the presence of different methylated β-CDs, including KLEPTOSE® CRYSMEβ. Both
cell types were shown to express basal levels of ABCA1 and SR-BI whereas ABCG1
was solely found in ABAE. Upon CD treatments, the percentage of membrane-extracted
cholesterol correlated to the methylation degree of the CDs independently of the lipid
composition of the cell membranes. Decreasing the cellular cholesterol content with
CDs led to reduce the expression levels of ABCA1 and ABCG1. In addition, the
cholesterol efflux to ApoA-I and HDL particles was significantly decreased suggesting
that cells forming the blood vessel wall are able to counteract the CD-induced loss
of cholesterol. Taken together, our observations suggest that methylated β-CDs can
significantly reduce the cellular cholesterol content of cells forming atherosclerotic lesions
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and can subsequently modulate the expression of ABC transporters involved in RCT. The
use of methylated β-CDs would represent a valuable and efficient tool to interfere with
atherosclerosis pathogenesis in patients, nonetheless their mode of action still needs
further investigations to be fully understood and finely controlled at the cellular level.
Keywords: aortic endothelial cells, atherosclerosis, ABCA1, ABCG1, cholesterol, methylated β-cyclodextrins,
reverse cholesterol transfer, smooth muscle cells
INTRODUCTION
Vascular dysfunction represents a key event in the pathogenesis
of atherosclerosis, a chronic disease characterized by the
increased deposition of cholesterol in the artery intima. In
the first steps of the disease, inflammatory processes lead to
the recruitment of cholesterol-laden macrophages in the artery
wall that form the so-called foam cells filled with numerous
cholesterol ester droplets (Allahverdian and Francis, 2010). An
additional mechanism for the generation of these foam cells
in atherosclerotic plaques is the conversion of smooth muscle
cells (SMCs) from the artery wall into foam cells (Allahverdian
et al., 2014). Studies focusing on the balance between lipid
accumulation and lipid removal from cells have highlighted
that the complex cholesterol metabolism is controlled by the
reverse cholesterol transport (RCT) which is mainly dependent
on the expression and activity of three prominent proteins
promoting the cellular cholesterol eﬄux (Phillips, 2014). Two
of them belong to the ATP-binding cassette (ABC) transporter
family comprising 48 members in humans (Kim et al., 2008) and
correspond to the first member of the sub-family A (ABCA1)
and the first member of the sub-family G (ABCG1). Studies in
macrophages revealed that apoA-I initially interacts with ABCA1
to form a partially lipidated discoidal complex that subsequently
interacts with ABCG1 in order to get additional cholesterol
and to generate spherical lipoprotein particles, the high density
lipoproteins (HDL) (Gelissen et al., 2006). The third protein
involved in the RCT is the scavenger receptor class B member 1
(SR-BI, encoded by SCARB1 gene) which mediates bidirectional
cholesterol exchanges between cell membrane and HDL. We and
others have investigated the expression pattern and functionality
of SR-BI and these two ABC transporters at the macrophage level
as well as their abilities to initiate and generate HDL (Linsel-
Nitschke and Tall, 2005; Wang et al., 2007; Mahmood et al., 2013;
Phillips, 2014). However the RCT has received little attention at
the arterial endothelial cell and SMC levels (Allahverdian and
Francis, 2010).
These studies clearly highlight the importance to characterize
the role of ABCA1, ABCG1, and SR-BI in order to prevent or to
develop targeted therapies to treat cardiovascular and metabolic
diseases. For this reason, current therapeutic perspectives in
atherosclerosis aim at promoting cholesterol eﬄux by a process
resulting in an increase in ABCA1 and ABCG1 expression
that generates higher amount of HDL. For example, activation
of the Liver X receptor (LXR) signaling pathway regulating
the ABCA1/ABCG1 expression have been shown to promote
macrophage RCT (Naik et al., 2006) and decrease atherosclerosis
in mouse models (Terasaka et al., 2003). Another efficient
approach consists in using molecules able to deplete the
cellular cholesterol content, for instance, the β-cyclodextrin
subset (β-CD). This latter one is member of the cyclodextrin
(CD) family which is composed of cyclic oligosaccharides
prepared from starch after an enzymatic cleavage. Amongst
CDs, β-CD consists of 7 D-glucopyranose units which possess
21 hydroxyl moieties. Its shape is a conical cylinder whose
inner surface is hydrophobic and outer surface hydrophilic
(Mahammad and Parmryd, 2015). These hydroxyl groups can
be modified via specific routes conferring particular biochemical
and biological properties to the CDs. For these reasons, β-CD
family is widely used in the pharmaceutical field to improve
dissolution rate, chemical stability and drug bioavailability.When
β-CD is partially methylated, the resulting compounds are
named methylated β-CDs and are able to interact with cell
membranes and thus influence their cholesterol/phospholipid
content (Mahammad and Parmryd, 2015). This process remains
however partially understood but could still be promising for
the treatment of patients suffering from abnormal cholesterol
storage diseases such as in the Niemann-Pick C (NPC) disease.
This disorder is characterized by an abnormal lysosomal lipid
storage caused by a genetic mutation in genes coding for
proteins involved in the intracellular cholesterol trafficking. In
vitro and in vivo studies have demonstrated that CDs are able
to trap membrane-stored cholesterol rendering them promising
therapeutic agents for novel treatments in patients with NPC
disease (Vance and Karten, 2014). Additionally, cyclodextrins
have recently shown therapeutic potential in Alzheimer disease
(AD) which is characterized by a cerebral accumulation of
amyloid peptides (Gosselet et al., 2013) and by a disturbed
brain cholesterol homeostasis (Gosselet et al., 2014). In a mouse
model of AD, Yao et al. demonstrated that hydroxypropyl-β-
CD reduces amyloid production and clearance probably via an
ABCA1-mediated process (Yao et al., 2012).
All these data have recently provoked an increased interest for
the use of cholesterol-sequestrating agents in the atherosclerosis
context. The anti-atherosclerotic action of KLEPTOSE R©
CRYSMEB, a family member of the methylated-β-CDs, has been
highlighted in atherosclerotic mouse models demonstrating
that this particular CD modifies HDL-cholesterol levels and
decreases cholesterol accumulation in atherosclerotic lesions
(Montecucco et al., 2015). However, no study focusing on the
effect of this CD on the RCT process in arterial endothelial cells
and in SMCs has been performed so far. Here we investigate
in vitro the effects of several methylated β-CDs including
KLEPTOSE R© CRYSMEβ on cholesterol regulation in aortic
bovine arch endothelial (ABAE) cells and SMCs. CDs were able
to extract membrane cholesterol from both cell types resulting
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in a decreased cellular cholesterol content. This decrease
in cellular cholesterol diminished the expression of ABCA1
and ABCG1, but not SR-BI expression, and reduced cellular
cholesterol release. In both cell types, treatment with the LXR
agonist T0901317 increased ABC transporter expressions and
promoted cholesterol release to ApoA-I and HDL. However
when cells were depleted in cholesterol by methylated β-CD
treatment, T0901317 only promoted cholesterol eﬄux in ABAE
cells. Therefore, by reducing the cellular cholesterol content,
our results demonstrate that methylated β-CDs can efficiently
interfere with the pathological process of atherosclerosis. Novel
in vivo and in vitro approaches would be necessary to further
characterize the therapeutic potential of these molecules to treat
atherosclerosis.
MATERIALS AND METHODS
Cyclodextrins (CDs)
Except for Rameβ which was provided by Sigma-Aldrich (Lyon,
France), the various cyclodextrins (CDs) were synthesized,
purified, modified and lyophilized by Roquette Frères (Lestrem,
France). Before the experiments, they were stored in a dry
place at room temperature. For experiments they were freshly
solubilized in Dulbecco’s modified Eagle’s medium (DMEM).
Table 1 recapitulates the different CDs used in this study and
their methylation degree (i.e., the number of methyl groups per
glucopyranose unit) and their molecular weight. Themethylation
degrees were determined by 1HNMR spectroscopy andMALDI-
TOF experiments.
Chemicals
ApoA-I and HDL were purchased from PROSCI Incorporated
(Poway, CA, USA). Bovine serum albumin (BSA) and T0901317
were purchased from Sigma-Aldrich. T0901317 was dissolved
and used as previously described (Saint-Pol et al., 2012). [3H]-
cholesterol (43 Ci/mmol) was purchased from PerkinElmer Life
and Analytical Sciences (Waltham, MA, USA).
Cell Culture
This study was carried out in accordance with the
recommendations of the French veterinary council’s guide
(approval n◦ B62-498-5). Aortic bovine arch endothelial
cells (ABAE) and bovine SMCs were extracted, purified and
characterized as previously published (Dehouck et al., 1994,
1997; Vandenhaute et al., 2011). Cells were cultured in 12 and
24-well plates coated with porcine skin gelatin (Sigma-Aldrich).
ABAE and SMCs were seeded at 25,000 and 50,000 cells per
TABLE 1 | Description of the different CDs used in this study.
Name Methylation degree Molecular weight (g/mol)
β-CD 0 1135
Methyl-β-CD 0.23 1157
KLEPTOSE® CRYSMEβ 0.57 1191
Rameβ 1.8 1311
well, respectively and cultured in DMEM supplemented with 2
mM glutamine, 50 µg/mL gentamycin, 1 ng/mL basic fibroblast
growth factor (bFGF) and with 10% (v/v) horse serum (HS) and
10% calf serum (CS) for ABAE and with 20% fetal calf serum
(FCS) for SMCs. When cells reached 60-80% of confluence,
treatment with CDs was initiated.
Cell Death
Cells were incubated for 24 h with increasing CD concentrations
(from 0.1 to 25mM) in DMEM supplemented with bFGF. The
control condition consisted in DMEM with bFGF. Cell death
was then quantified using the Cyto-ToxONE Homogeneous
Membrane Integrity Assay (Promega, Madison, WI, USA)
following supplier’s instructions. Briefly, this kit measures the
release of the lactate dehydrogenase (LDH) by cells with damaged
membranes. Colorimetric values were measured using the
Synergy
TM
H1 (Biotek, Shoreline, WA, USA) and data represent
the percentage of cell death compared with a 100% cell death
control which corresponds to the total lysis of a cell sample using
the lysis buffer provided in the kit.
mRNA Extraction and Real Time RT-PCR
Analysis
Twenty-four hours after treatment with 1mM CDs
supplemented or not with 10 µM T0901317, ABAE and
SMCs were rinsed twice with cold phosphate-buffered saline
(8 g/L NaCl, 0.2 g/L KCl, 0.2 g/L KH2PO4, 2.87 g/L NA2HPO4
(12H2O), pH 7.4) and then lysed in 200 µL RLT lysis buffer
(Qiagen, Venlo, the Netherlands). Three wells per condition were
pooled and mRNA purification was performed using the RNeasy
total RNA extraction kit (Qiagen) following manufacturer’s
instructions. The purity and the concentration of the extracted
mRNA were assessed by measuring the absorbance at 260,
280, and 320 nm using the Tek3 microplate reader protocol
(Synergy
TM
H1, Biotek). Only mRNA samples with high purity
values (>2) were used in our studies. For each condition, cDNAs
were obtained from 0.250mg of mRNA using iScript
TM
Reverse
Transcription Supermix (BioRad, Hercules, CA, USA) according
to manufacturer’s instructions. Real-time PCR experiments were
performed using the Sso Fast EvaGreen Master Mix kit (BioRad)
and custom primers (listed in Table 2) which were used in our
previous studies (Saint-Pol et al., 2012, 2013). For each primer,
amplification was carried out for 40 cycles with an annealing
temperature of 60◦C using a CFX96 thermocycler (BioRad). The
amplification efficiency was determined for each primer pair
and used in the calculation method (CFX Manager, BioRad).
Melting curve analysis was performed after amplification cycles
in order to check the specificity/purity of each amplification.
Gene expression levels were evaluated according to the 11Ct
method and were normalized against ß-ACTIN.
Protein Extraction and Analysis
After a 24 h treatment with CDs (1mM) supplemented or
not with 10 µM T0910317, cells were washed twice with cold
PBS and lysed in 100 µL RIPA buffer (50 mM Tris-HCl
(pH 7.4), 150mM NaCl, 0.25% deoxycholic acid, 1% NP-40,
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TABLE 2 | Primers designed for real time RT-PCR.
mRNA Species F/R Sequences Accession
Number
ABCA1 Bos taurus F 5′-gtgtctcgcctgttctcag-3′ NM_001024693
R 5′-gaaacatcacctcctgccg-3′
ABCG1 Homo sapiens F 5′-gaggaagaaaggatacaagacc-3′ BC029158
R 5′-gtcagtatctccttgaccattt-3′
SCARB1 Bos taurus F 5′-cccttaatccacctcatcaatc-3′ NM_174597
R 5′-gaagtttttgacccctgtgaac-3′
ß-ACTIN Bos taurus F 5′-gcacaggcctctcgccttcg-3′ NM_173979
R 5′-acatgccggagccgttgtcg-3′
From left to right: mRNA targeted for amplification, species, sequences (Forward (F),
Reverse (R) primer), and mRNA accession numbers in NCBI database.
and 1 mM EDTA) supplemented with protease/phosphatase
inhibitors (Sigma-aldrich). Six wells of a 12-well plate per
condition were pooled. Protein concentration was then assessed
using Bradford method (Biorad). Afterwards, proteins (40
µg/condition for ABAE and 20 µg/condition for SMCs) were
separated on a 4–15% sodium dodecyl sulfate polyacrylamide gel
(BioRad) and electrotransferred onto nitrocellulose membranes
(GE Healthcare, Barrington, IL, USA). After a 90 min incubation
in blocking buffer (25mM Tris-HCl (pH 8.0), 125mM NaCl,
0.1% Tween 20 and 5% skimmedmilk) at 37◦C, membranes were
incubated at 4◦C overnight with either mouse anti-ABCA1 (2
µg/mL, ABCAM, Paris, France) or rabbit anti-ABCG1 (5µg/mL,
ABCAM) or rabbit anti-SR-BI (0.4 µg/mL, ABCAM) and mouse
anti-β-ACTIN antibody (1 µg/mL, Sigma-aldrich). Afterwards,
membranes were washed three times in blocking buffer and
incubated with their appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody (Dako, Glostrup, Denmark)
for 1 h at room temperature. HRP was detected with an
enhanced chemiluminescence kit (GE Healthcare) and revealed
on chemiluminescence-sensitive films (GE Healthcare). Optical
band densities were measured using TotalLab TL 100 1D
Gel Analysis software (Non-linear Dynamics, Newcastle, UK).
In these experiments β-ACTIN was used as the loading
control.
Cholesterol Depletion and Cellular
Cholesterol Efflux from ABAE and SMCs
First, [3H]-cholesterol (0.5 µCi/mL) was incorporated in the
serum (10% HS/CS for ABAE and 20% FCS for SMCs, as
described above) for 6 h at 37◦C. The resulting radiolabeled
serum was then supplemented with 1 ng/mL bFGF, 2 mM
glutamine, and 50 µg/mL gentamycin in order to obtain a [3H]-
cholesterol enriched-medium in which cells in 12-well plates
were cultured for 36 h. Afterwards, cells were rinsed twice with
DMEM/0.1% Bovine serum albumin (BSA) and cultured in 1.4
mL DMEM/1 ng/mL bFGF supplemented or not with 1 mM
CDs for 24 h at 37◦C in 5% CO2. After a 2 h incubation period,
500 µL of medium were removed and the amounts of [3H]-
cholesterol measured in order to evaluate the effect of CDs on
the cell membrane extraction of [3H]-cholesterol. To this aim,
medium samples were centrifuged (4 min, 4000 rpm, 4◦C) to
remove cellular debris and the amounts of [3H] measured with
a scintillation counter (TriCarb 2100TR, PerkinElmer).
Cell extracted [3H]-cholesterol by CDs and cellular cholesterol
amounts, expressed in disintegration per minute (DPM), were
obtained using the following equation:
Cell extracted[3H]-cholesterol by CDs
= DPMmedia 2 h∗(1.4/0.5)
Values were then converted in percentage and compared with
the control condition (no CD supplementation in medium)
which was set to 100%. To evaluate the effect of the CDs on
the RCT, cells were treated 24 h with different CDs at 1mM in
[3H]-cholesterol enriched-medium. Afterwards cells were rinsed
twice with DMEM/0.1% BSA and cellular cholesterol eﬄux
was assessed for 6 h in absence or presence of cholesterol
acceptors (20µg/mLApoA-I or 50µg/mLHDL) in DMEM/0.1%
BSA. At the end of this step, cell medium supernatants were
collected and centrifuged (4 min, 4000 rpm, 4◦C) whereas cells
were lysed in 1% Triton X-100 in PBS after 4 washes in cold
PBS. Ultimately 3H-radioactivity was measured in supernatants
and cell lysates using the scintillation counter described above.
Protein concentration was also assessed in each sample using the
Bradford method and final results in Figures 6, 9 were expressed
as the amount of DPM measured/sample divided by its protein
concentration in microgram.
In Figure 7, results were presented as previously described
(Saint-Pol et al., 2012, 2013; Kuntz et al., 2015) and consist in
calculating the percentage of cholesterol eﬄux while taking into
account the remaining cellular cholesterol load, following this
formula:
% cholesterol eﬄux = (DPMMEDIUM/(DPMMEDIUM
+DPMCELL LYSATE))× 100
To assess the effect of T0901317 in ABAE cells and SMCs
(Figure 9), this LXR-agonist was added in the media during
Rameβ-treatment at a concentration of 10 µM. Then, cholesterol
eﬄux was measured as described above. Control condition
(medium alone, not supplemented with neither Rameβ nor
T0901317 but only with adequate volume of DMSO) was set to
100%. Each experiment was performed in triplicate and repeated
twice.
Statistics
Statistical analyses were performed using the GraphPad Prism
5.01 R© software (Graphpad software, La Jolla, USA). Results were
analyzed and compared together using appropriate post-hoc tests
(see figure legend) where, ∗p< 0.05; ∗∗p< 0.01; ∗∗∗p< 0.001; and
##p< 0.01.
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RESULTS
ABCA1, ABCG1, and SCARB1 Gene
Expression in ABAE and SMCs
ABCA1, ABCG1, and SCARB1 expressions were investigated in
aortic endothelial cells (ABAE) and in SMCs with real time RT-
PCR method using primers described in Table 2. Figure 1 shows
that ABCA1 and SCARB1 expression was detected in both cell
types whereas ABCG1 was only found in ABAE not in SMCs. In
our culture conditions (DMEM), we observed that the amount
of ABCG1 and SCARB1 mRNA expressed in ABAE were 2.33-
fold and 13.20-fold higher than the amount of ABCA1 mRNA,
respectively. In SMCs, SCARB1 was expressed 9.14-fold more
than ABCA1.
Cellular Cholesterol Efflux from ABAE and
SMCs
Figure 2A shows cholesterol accumulation in ABAE and SMCs.
Cholesterol accumulated three-fold less in ABAE than in SMCs
(17,918 ± 1319 DPM/µg of proteins vs. 47,672 ± 2633 DPM/µg
of proteins, respectively). Cholesterol eﬄux was then assessed in
ABAE and in SMCs in the absence (BSA only, control condition)
or in the presence of cholesterol acceptors (BSA supplemented
either with ApoA-I or with HDL) (Figure 2B). Without
any cholesterol acceptor (control condition), the amount of
cholesterol released from SMCs was more important than the
one released from ABAE by two-fold (1635 vs. 865 DPM/µg of
proteins, respectively). In the presence of either ApoA-I or HDL,
the eﬄux was 1043 and 2395 DPM/µg of proteins, respectively
in ABAE, and 1639 and 4701 DPM/µg of proteins, respectively
in SMCs. These results suggest that in SMCs and in ABAE,
ApoA-I does not promote cholesterol eﬄux from cell membrane
in contrast to HDL as previously reported for other cell types
FIGURE 1 | mRNA expression of ABCA1, ABCG1, and SCARB1 in ABAE
and SMCs by real time RT-PCR. Each bar represents the absolute
quantification of the three studied gene. Used primers are listed in Table 1.
ABCA1 expression level is used as the reference level and set to 1. ABCG1
expression was not detected in SMCs. Results correspond to the mean ± SD
of three different experiments pooled from three wells. n.d: not detected.
One-way ANOVA test followed by Bonferroni correction was performed in
which ***p < 0.001; **p < 0.01 when compared with the ABCA1 expression.
(Saint-Pol et al., 2012, 2013). Additionally, when comparing the
cholesterol eﬄux to HDL, our results shows that cholesterol
eﬄux to HDL particles was much more effective from SMCs than
from ABAE.
Effects of the Different Methylated CDs on
the Cellular Cholesterol Content in ABAE
and SMCs
Before assessing the effects of differentially methylated β-
cyclodextrins on the cellular cholesterol content (RCT), we
performed viability tests using increasing concentration of CDs
(0.1, 0.5, 1, 2.5, 5, 10, and 25 mM). In comparison to SMCs,
FIGURE 2 | Cholesterol efflux from ABAE and SMCs. Cells were first
labeled with [3H]-cholesterol (0.5 µCi/mL) for 36 h at 37◦C and then
equilibrated for 24 h in DMEM/0.05% BSA at 37◦C. Cellular [3H]-cholesterol
loads in DPM per µg of proteins were compared between ABAE and SMCs
(A). Data represent the mean ± SEM (in DPM/µg of proteins), with n = 6 from
two sets of experiments. Paired-t-test was performed, ***p < 0.001 when
compared with ABAE condition. [3H]-cholesterol released from both cell types
was then measured 6 h after medium supplementation with either BSA (control
condition) or cholesterol acceptors [ApoA-I (20 µg/mL) or HDL (50 µg/mL)] at
37◦C (B). Data represent the mean ± SEM (in DPM/µg of proteins), with n = 6
from two sets of experiments. One-way ANOVA test followed by Bonferroni
correction was performed in which ***p < 0.001 refers to the control condition
and ###p < 0.001 refers to the matched HDL condition in ABAE.
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TABLE 3 | Determination of the toxicity of the CDs.
Name Toxic concentration
threshold determined for
ABAE (in mM)
Toxic concentration
threshold determined for
SMCs (in mM)
β-CD 5 2.5
Methyl-β-CD 10 2.5
KLEPTOSE® CRYSMEβ 10 2.5
Rameβ 5 2.5
ABAE and SMCs were treated for 24 h with increasing concentrations (0.1, 0.5, 1, 2.5,
5, 10, and 25 mM) of the appropriate CD (described in Table 1). Afterwards, the lactate
dehydrogenase activity in cells was measured for each CD concentration and compared
with controls in order to estimate cell death induced by CDs. Each experiment was
performed in triplicate and repeated three times.
ABAE appeared more resistant to the same CD treatment as cell
toxicity could only be detected at 5mM for β-CD and Rameβ,
and at 10mM for the KLEPTOSE R© CRYSMEβ and Methyl-
β-CD (Table 3). In SMCs, no toxicity was detected below a
concentration of 2.5mM for any CD tested. Therefore to avoid
any artifact due to CD-induced cell death (Kiss et al., 2010;
Mahammad and Parmryd, 2015), the concentration of 1mMwas
selected for further experiments.
After 2 h of treatment with 1 mM of the appropriate
CDs, we observed that, independently to the cell type, the
β-CD (methylation degree 0, Table 1) was able to extract
more than 580% of cholesterol when compared with the
respective ABAE and SMC control condition (no CD
treatment) (Figure 3). Methyl-β-CD (methylation degree
0.23), KLEPTOSE R© CRYSMEβ (methylation degree 0.57) and
Rameβ (methylation degree 1.8) were able to extract 350.4, 507.1,
and 1216.9% of cholesterol, respectively. Despite the fact that
ABAE accumulated less cholesterol than SMCs (Figure 2A),
percentages of extracted-cholesterol were identical between both
cell types for each evaluated CD. Therefore, we can conclude
that cholesterol extraction rather depends on the methylation
degree of the CDs and not on the cell type. As also shown in
Figure 3, cholesterol cellular content in SMCs and in ABAE
varied proportionally to the capture of cholesterol by CDs when
compared with the untreated condition. In ABAE, β-CD and
Rameβ decreased the cholesterol cellular content to 11,015
and 6162 DPM/µg of proteins (representing a decrease by
38.52 and 65.6%, respectively) whereas Methyl-β-CD and
KLEPTOSE R© CRYSMEβ decreased it to 14,892 and 13,022
DPM/µg of proteins, respectively (a decrease by 16.9 and
27.3%, respectively). In SMCs, β-CD and Rameβ decreased the
cholesterol cellular content to 25,276 and 15,298 DPM/µg of
proteins, respectively (by 47.0 and 67.9%, respectively) whereas
Methyl-β-CD and KLEPTOSE R© CRYSMEβ decreased it to
34,408 and 27,539 DPM/µg of proteins, respectively (by 42.2 and
27.3%, respectively).
Effects of the Methylated β-CDs on the
Reverse Cholesterol Transport
To determine whether the cholesterol depletion induced by
CD treatment may impact the cellular cholesterol metabolism,
transcriptional and protein expressions of key players of
FIGURE 3 | Cellular cholesterol extraction (continuous lines) and
cellular cholesterol content (dashed lines) in cyclodextrin-treated
ABAE (open symbols) and SMCs (solid symbols). Cells were first labeled
with [3H]-cholesterol (0.5 µCi/mL) for 36 h at 37◦C and then equilibrated in
DMEM/0.05% BSA for 24 h at 37◦C. After a 2 h incubation period with
different CDs (1 mM), the amounts of [3H]-cholesterol contained in the
medium (in percentage) and within the cells (in DPM/µg of proteins) were
measured. For cholesterol extraction data, all results referred to control
condition (no CD, only DMEM) which is set to 100%. Data are expressed as
the mean ± SEM (n = 15).
the reverse cholesterol transfer (RCT), i.e., ABCA1, ABCG1,
and SR-BI, were investigated by real time RT-PCR and
immunoblotting. In ABAE, mRNA expression of ABCA1 and
ABCG1 was significantly down-regulated in all evaluated CD
conditions (Figures 4A,C, respectively) compared with control.
Such decrease in gene transcription was confirmed at the protein
level for both ABCA1 (Figure 4B) and ABCG1 (Figure 4D). The
expression of SR-BI was not modified by any CD treatment
(Figures 4E,F). In SMCs, no expression of ABCG1 was detected
at mRNA and protein levels, neither before nor after any CD
treatment (data not shown). However, the transcriptional and
protein expression of ABCA1 was significantly decreased for
each tested CD condition (Figures 5A,B) compared with control.
As previously observed in ABAE cells, the expression of SR-BI
in SMCs was not significantly modified by any CD treatment
(Figures 5C,D).
Next, aiming at investigating the consequences of CD-
mediated ABCA1/ABCG1 down-regulation on the cellular
cholesterol eﬄux, ABAE and SMCs were labeled with [3H]-
cholesterol and the cholesterol release, mediated via lipid-free
apoA-I or HDL particles, was then measured (Figure 6). In
ABAE, a significant decrease in the cholesterol eﬄux to ApoA-
I (Figure 6A) and to HDL (Figure 6C) particles was observed. In
fact, β-CD, Methyl-β-CD, KLEPTOSE R© CRYSMEβ and Rameβ
decreased the ApoA-I-mediated cholesterol release by 46.26,
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FIGURE 4 | Evaluation of the expressions of ABCA1, ABCG1, and SR-BI upon CD-treatment in ABAE. Twenty-four hours after treatment (CDs 1 mM, solid
bars), mRNA expressions of ABCA1 (A), ABCG1 (C) as well as of SCARB1 (E) were assessed and compared with control (DMEM treatment, open bar). Each bar
represents the mRNA expression normalized against the housekeeping gene β-ACTIN ± SEM (n = 6). Control condition (without CD treatment) is used as the reference
level and set to 1. A one-way ANOVA test followed by Dunnett’s test for multiple comparisons was applied with *p < 0.05; **p < 0.01; ***p < 0.001 compared with
control. Normalized protein expression levels for ABCA1 (B), ABCG1 (D), and SR-BI (F) were assessed by immunoblotting. β-ACTIN was used as the loading control.
Results correspond to the optical density measured in three experiments. Control condition (without any CD treatment) is used as the reference level and set to 1.
18.41, 45.19, and by 59.07%, respectively (Figure 6A) and the
HDL-mediated cholesterol eﬄux was reduced by 39.94, 34.25,
32.05, and by 63.75%, respectively (Figure 6C). In SMCs, except
for methyl-β-CD and Rameβ conditions in which the decrease
in cholesterol eﬄux reached 25.25 and 43.49% respectively,
the other CDs did not significantly alter cholesterol release to
ApoA-I particles (Figure 6B). On the contrary, cholesterol eﬄux
to HDL was significantly decreased by β-CD, Methyl-β-CD,
KLEPTOSE R© CRYSMEβ and Rameβ, by 14.75, 15.12, 29.46, and
by 60.21%, respectively (Figure 6D).
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FIGURE 5 | Evaluation of the expressions of ABCA1 and SR-BI upon CD-treatment in SMCs. Twenty-four hours after treatment (CDs 1 mM, solid bars),
mRNA expressions of ABCA1 (A) and SCARB1 (C) were assessed and compared with control (DMEM treatment, open bar). Each bar represents the mRNA
expression normalized against the housekeeping gene β-ACTIN ± SEM (n = 6). Control condition (without CD treatment) is used as the reference level and set to 1. A
one-way ANOVA test followed by Dunnett’s test for multiple comparisons was applied with ***p < 0.001 compared with control. Normalized protein expression levels
for ABCA1 (B) and SR-BI (D) were assessed by immunoblotting. β-ACTIN was used as the loading control. Results correspond to the optical density measured in
three experiments. Control condition (without any CD treatment) is used as the reference level and set to 1.
It is now well-described that sterol concentration in cell
membrane as well as cholesterol pool in whole body remain
quite constant (Dietschy and Turley, 2004), therefore data
from Figure 6 were additionally analyzed with another method
consisting in taking into account the total cholesterol load
in cell after CD-depletion (see Material and Methods). In
ABAE cells, the percentage of ApoA-I and HDL-mediated
cholesterol eﬄuxes was significantly slightly decreased when
compared with control condition (Figures 7A,C) whereas
no significant differences were reported in SMCs when
compared with control condition, except for Rameβ condition
(Figures 7B,D) in which an increase in the percentage of
ApoA-I-mediated cholesterol eﬄux was observed. These
results suggest that when the intracellular cholesterol content
decreased (due to CD treatment in this case), the associated
downregulation of ABC transporters provoked a decrease of
the cholesterol eﬄux in order to maintain a quite stable and
continuous flow of cholesterol exchanges between cells and
media/plasma.
Effect of T0901317 on RCT
To determine whether the synthetic LXR-agonist T0901317
would partially reverse the effect of CD treatment observed in
Figure 6 for ABAE and SMCs, these cells were treated with
both 1 mM Rameβ and 10 µM T0901317. In ABAE cells,
T0901317 treatment increased mRNA and protein expression
levels of ABCA1 and ABCG1 as well as together with Rameβ
treatment compared with control condition (DMEM alone)
(Figure 8A). As previously reported by us in other cell types,
the expression of SR-BI was not modified by the LXR-agonist
treatment (Saint-Pol et al., 2012, 2013) (Figure 8A). Then,
LXR-treatment induced higher cholesterol eﬄuxes to ApoA-I
and HDL in ABAE (289 and 162% when compared with the
control condition (100%) respectively, Figure 9A). As reported
in Figures 6A,C, ABAE treated with Rameβ showed a decrease in
the cholesterol release to ApoA-I and HDL, however, cholesterol
eﬄux get significantly higher when cells were treated together
with Rameβ and T0901317 (40% when treated with rameβ
alone vs. 96% when treated with Rameβ + T0901317 in the
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FIGURE 6 | Cholesterol release from ABAE (A,C) and from SMCs (B,D) upon CD-treatment. Cells were first labeled with [3H]-cholesterol (0.5 µCi/mL) for 36 h
at 37◦C and then equilibrated in DMEM/0.05% BSA for 24 h at 37◦C. [3H]-cholesterol released in the medium from both cell types was then measured 6 h after
medium supplementation with cholesterol acceptors [ApoA-I (20 µg/mL) or HDL (50 µg/mL)] at 37◦C. The radioactivity contained in the culture medium, that
corresponds to the cholesterol released from cells was measured. Data are expressed as the mean ± SEM (in DPM/µg of proteins, n = 6 from two sets of
experiments). Statistical analysis: a one-way ANOVA followed by Dunnett’s test for multiple comparisons in which *p < 0.05; ***p < 0.001 compared with the control
condition (open bars) without any CD treatment.
presence of ApoA-I and 50% when treated with rameβ alone vs.
72% when treated with Rameβ + T0901317 in the presence of
HDL) (Figure 9A). In SMCs, ABCA1 expression was increased
whereas SR-BI expression was not (Figure 8B). As observed
in ABAE, treatment of SMCs with T0901317 resulted in an
increase in cholesterol release to ApoA-I and HDL (404 and
248%, respectively) (Figure 9B). As previously described, when
these cells were treated with Rameβ a significant decrease in the
cholesterol eﬄux to ApoA-I and HDL was observed (30 and
44% when compared with the control condition, respectively)
however the addition of T0901317 to Rameβ treatment did not
increase significantly cholesterol release in CD-depleted SMCs
(31 and 45%, respectively).
DISCUSSION
Atherosclerosis is characterized by inflammatory processes
leading to an abnormal accumulation of cholesterol in the artery
vessel wall. This event results from an imbalance between the
accumulation and the eﬄux of cholesterol in macrophages,
endothelial cells, and SMCs (Kruth, 2001). In health, these cells
do have specific pathways involved in cholesterol export/transfer
to extracellular HDL via the so-called RCT. This process remains
the major pathway for regulating cellular cholesterol pools
and is mediated by proteins expressed by most cell types: two
members of the ATP-binding cassette (ABC) transporter family,
ABCA1 and ABCG1, and SR-BI (Phillips, 2014). However in
atherosclerotic arteries it has been reported that macrophages,
SMCs and arterial endothelial cells display altered expressions
of these ABC transporters. Although some studies report
an up-regulation of ABCA1 and ABCG1 expression, others
show a decreased SR-BI and ABC transporter expressions in
atherosclerotic arteries when compared with intact or less
affected arteries (Albrecht et al., 2004; Forcheron et al., 2005;
Soumian et al., 2005; Choi et al., 2009; Ishikawa et al., 2009).
Nevertheless, it is now well-approved that ABCA1, ABCG1,
and SR-BI represent three major key players in atherosclerosis.
Modulating their level of expression and/or functionality, which
in turns would affect the amount of plasmatic HDL, is now
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FIGURE 7 | Percentage of cholesterol release from ABAE (A,C) and from SMCs (B,D) upon CD-treatment taking into account the cholesterol load at
the start of the experiments. Results showed here are the same as the ones from Figure 6 but the cellular cholesterol content remained in cells after cholesterol
efflux was taken into account in the calculation method. A one-way ANOVA test followed by Dunnett’s test for multiple comparisons was applied with *p < 0.05
compared with control condition.
considered as a valuable and promising therapeutic approach
to treat atherosclerosis (Tuteja and Rader, 2014). In line with
these considerations, recent treatments with KLEPTOSE R©
CRYSMEβ has shown to improve atherogenesis in ApoE−/−
mice by ameliorating plasmatic HDL amounts and by abrogating
some inflammatory processes (Montecucco et al., 2015). This
molecule belongs to the cyclodextrin (CD) family whose
members are well-known to interact with cell membranes
and to extract their membrane cholesterol. In their study,
Montecucco and colleagues have essentially investigated the
effects of KLEPTOSE R© CRYSMEβ on the immune response and
inflammatory processes. They observed that both atherosclerotic
plaque size and T lymphocyte content are reduced upon CD
treatment, highlighting the fact that KLEPTOSE R© CRYSMEβ
reduces the Th1-mediated immune response. However, the
authors have not investigated the impact of this CD on the SMC
and aortic endothelial cell RCT. Therefore we investigated the
effects of a number of CDs differentially methylated, including
KLEPTOSE R© CRYSMEβ, on cholesterol accumulation, RCT and
HDL genesis in both SMCs and aortic bovine endothelial cells
(ABAE).
Overall, our results suggest that RCT occurs in a different
manner in SMCs as compared with endothelial cells. In the
same culture conditions, we observed that the cholesterol load
was higher in SMCs than in ABAE. Subsequently, this load
resulted in a higher cholesterol eﬄux from SMCs compared
to ABAE. However, when correlated with the cholesterol load,
the rate of HDL-mediated cholesterol eﬄux was higher in
ABAE than in SMCs (represented 16.20 ± 1.87% and 10.90 ±
1.3% for ABAE and SMCs, respectively) demonstrating a better
ability of ABAE cells to export cholesterol to HDL particles.
In accordance with these results, it was previously reported
that, contrary to SMCs, endothelial cells from arteries exhibit
few lipid accumulation however the reasons remain unknown
(Phillips, 2014). Therefore such phenomenon could be explained
by the fact that aortic endothelial cells express both ABCA1 and
ABCG1 whereas SMCs only express ABCA1, no ABCG1, thus
decreasing the ability of SMCs to expel the cellular cholesterol.
In fact, ABCG1 is known to be expressed in endosomes in
which it promotes cholesterol transfer to the plasma membrane
(Tarling and Edwards, 2011). Therefore it is likely that the
lack of ABCG1 expression contributes to entrap cholesterol in
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FIGURE 8 | Effect of 10 µM T0901317 on ABCA1, ABCG1, and SR-BI expression in ABAE (A) and SMCs (B) treated or not with Rameβ. Cells were first
labeled as previously described and then treated with 1 mM of Rameβ supplemented or not with 10 µM T0901317. Transcriptional and protein expression of ABCA1,
ABCG1, and SR-BI were studied by real-time PCR and immunoblot in ABAE (A) and SMCs (B) and compared with control (DMSO treatment, open bar). For mRNA
study, each bar represents the mRNA expression normalized against the housekeeping gene β-ACTIN ± SEM (n = 6). For protein expression study, β-ACTIN was
used as the loading control and results correspond to the optical density measured in two independent experiments performed in triplicate. Control condition is used
as the reference level and set to 1. A one-way ANOVA test followed by Dunnett’s test for multiple comparisons was applied with **p < 0.01; ***p < 0.001 compared
with control condition.
SMCs. Interestingly, this specificity was also observed in other
vascular beds such as in the brain vasculature in which brain
pericytes and cerebral SMCs do not express ABCG1 whereas
brain capillary endothelial cells do (Gosselet et al., 2009; Saint-Pol
et al., 2012).
The difference between SMCs and ABAE in their cholesterol
metabolism was also observed after cholesterol depletion by
CDs as well as after T0901317 treatment. The amount of
extracted cholesterol by each tested CD was quite similar in
ABAE and in SMCs. However, endothelial cells compensated
their cholesterol depletion by decreasing their cholesterol eﬄux
whereas this process was very much less visible in SMCs.
To gain insight into the link between cholesterol loss and
cholesterol eﬄux, we evaluated the initial cellular cholesterol
load at the start of the eﬄux experiment and the percentage
of cholesterol eﬄux was calculated taking into account this
value. We observed that the percentage of cholesterol eﬄux
was slightly but significantly decreased in ABAE but not
in SMCs. Our results also suggest that this reduction in
cholesterol content due to CD treatment induced a decrease
in cholesterol eﬄux probably in order to maintain an almost
stable and continuous flow of cholesterol exchanges between
cells and media according to their intracellular cholesterol
content.
Our study also reports that CD-mediated cholesterol
extraction decreased the transcriptional expression of protein-
encoded genes regulating the RCT, such as ABCA1 and ABCG1
but did not modulate SR-BI expression. To our knowledge
the links between membrane cholesterol content and ABC
transporter expression remains unclear although it is likely that
cholesterol extraction may disrupt lipid rafts, which in turn
modify cell signaling pathways and cell physiology (Maclellan
et al., 2005; Portilho et al., 2012; Possidonio et al., 2014; Shirao
et al., 2015). One of the possible pathways impacted by lipid raft
disorganization could be the nuclear LXR pathway that controls
ABCA1 and ABCG1 expression in several cell types. When LXRs
are stimulated by natural or synthetic ligands, or when cells are
loaded with cholesterol, transcriptional expressions of ABCA1,
and ABCG1 are induced and lead to an increase in cholesterol
release to ApoA-I, ApoE, or HDL (Hirsch-Reinshagen and
Wellington, 2007; Saint-Pol et al., 2012, 2013; Gosselet et al.,
2014; Koldamova et al., 2014). In our case, the cholesterol
depletion induced by CD treatment decreased the expression
of both ABC transporters correlating with a decrease in the
cholesterol release from cells and more strikingly from ABAE.
Thus, it is likely that the action of CDs inhibits LXR signaling
pathway. To test this hypothesis and to better characterize
the link between ABC transporter expression and cholesterol
release/content, we tested the effect of the synthetic LXR agonist
T0901317 on ABAE and SMCs. As expected, we observed an
increase in the ABCA1 and ABCG1 expressions as well as an
increase in the ApoA-I- and HDL-mediated cholesterol eﬄux
from ABAE upon T0901317. When these endothelial cells were
concomitantly depleted in cholesterol by CD treatment, these
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FIGURE 9 | Effect of 10 µM T0901317 on cholesterol efflux to ApoA-I and HDL in ABAE (A) and SMCs (B) treated or nor with Rameβ. Cells were first
labeled with [3H]-cholesterol as previously described and incubated in the presence of 1 mM Rameβ, 10 µM T0901317 or both during 24 h. Then, [3H]-cholesterol
released in the medium from both cell types was measured 6 h after medium supplementation with either ApoA-I (20 µg/mL) or HDL (50 µg/mL). Data are expressed
as the mean ± SEM (in DPM/µg of proteins, n = 6 from two sets of experiments). Control condition (without any treatment) is used as the reference level and set to
100%. Statistical analysis: a one-way ANOVA followed by Dunnett’s test for multiple comparisons in which *p < 0.05; **p < 0.01; ***p < 0.001 compared with the
untreated condition (Control condition, open bars) and in which ##p < 0.01 when Rameβ + T0901317 condition was compared with Rameβ condition.
processes also occurred. However, in SMCs the increase in
ABCA1 expression was correlated with an increase in their
cholesterol eﬄux only when cells were treated with T0901317
in the absence of CD. This discrepancy confirms our previous
observation stating that cholesterol metabolism is different in
ABAE and SMCs. These finding needs further investigations
to fully understand why LXR activation after a CD-treatment
do not induce any effect on cholesterol release in SMCs. One
possibility is that such process may represent a safety mechanism
in order to limit the cellular cholesterol outflow and its resulting
cell death.
Our study also raises some questions regarding the exact role
of ABC transporters in RCT mechanism in ABAE and SMCs. In
SMCs, although ABCA1 expression was enhanced by T0901317
treatment together with Rameβ treatment, cholesterol eﬄux
was not rescued. Additionally in ABAE, T0901317 treatment
induced an increased in both ABCA1 and ABCG1 expressions
to the same degree in addition to Rameβ treatment or not, but
cholesterol eﬄux was only partially rescued. Therefore, we can
clearly assume that other unidentified transporters involved in
cholesterol exchanges would mediate this process in these cell
types or that transporter relocalization would occur and influence
cholesterol eﬄux.
Although we report a decrease in HDL synthesis by ABAE
and SMCs, a recent study from Montecucco and colleagues
reports an increase in plasmatic HDL content in ApoE-depleted
transgenic mice after intraperitoneal injections of KLEPTOSE R©
CRYSMEβ (Montecucco et al., 2015).We cannot exclude that this
discrepancy might be due to the fact that the cells we used in
our in vitro studies were not depleted in ApoE gene expression
or whether these cells were not cholesterol-loaded. Moreover,
different regulation, expression or functionality of ABCG1,
ABCA1, and SR-BI occurring in the liver of ApoE-depleted mice
as compared with the wild type situation would also explain the
increase of HDL reported in vivo (Montecucco et al., 2015).
Importantly, independently of the lipid and protein contents
of cell membranes between SMCs and ABAE, each CD
investigated in this study displays similar cholesterol depletion
abilities in both cell types. These observations suggest that
the percentage of extracted cholesterol rather depends on the
methylation degree of the CDs than in the cell membrane
composition or cell content. This cholesterol extraction process
induced by CDs is not well-characterized yet but seems to
depend on the CD distribution on the cell surface (López
et al., 2011). It has recently been suggested that CDs are
able to passively diffuse into the lipid bilayer by pointing
their opened secondary rim toward the lipidic polar groups
and then remain anchored to the phosphate and glycerol-ester
groups via hydrogen bond formation (Khuntawee et al., 2015).
Noteworthy, we observed that the methylation degree greatly
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influences the ability of CDs to extract cholesterol from both cell
types. We clearly demonstrated that β-CD and Rameβ represent
the most efficient CDs able to extract membrane cholesterol
whereas KLEPTOSE R© CRYSMEβ and Methyl-β-CD extracted
intermediate amounts of cholesterol. This is of prime importance
as aberrant cellular cholesterol depletion causing cell deaths are
widely reported in the literature upon CD treatment (Kiss et al.,
2010; Mahammad and Parmryd, 2015). Further investigations
based on the amelioration of design/targeted methylation of the
CDs would greatly improve and optimize their effects at the
cellular level.
To conclude, our study provides new evidence thatmethylated
β-CDs can efficiently interfere with the pathological process
of atherosclerosis by depleting cholesterol content in cells.
In response to this cholesterol depletion, cells may modulate
ABCA1 and ABCG1 gene expression, regulating in turn their
own cholesterol content and vice versa. These results are of
great importance in the rational design of efficient CD-based
therapeutic approaches, nonetheless, further in vitro and in vivo
studies are still necessary to evaluate the potential of β-CDs to
treat atherosclerotic patients.
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